The approval of Zalpin,  another interferon, is awaited later this year. The advantage of this drug is that it would be injected once every two weeks instead of once a week and this would cut down on injection related side effects.

http://in.reuters.com/article/businessNews/idINIndia-46039720100209

More information on Zalbin:

http://www.hgsi.com/albuferona-albinterferon-alfa-2b.html

This entry was posted on Wednesday, February 10th, 2010 at 10:36 AM and is filed under Research & Development. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.